Not actually the question since countries with modern healthcare systems provide all types of insulin at an average cost per unit that is roughly 1/10th to 1/20th the cost in the United States (cheap vs. expensive is an over simplification).
We should ask what are the outcomes that these systems produce, not how new the drugs are.
A cutting-edge healthcare system plagued by inequality and extreme costs can produce worse results than a more efficient healthcare system which is not as high-tech.
But yes, I agree. Sometimes the juice isn’t worth the squeeze.
Just repeating the question, when I gave you the answer, isn't very productive.